Drug
Camostat clinical trials
Also written FOY-305 and DWJ1248.
- studies test it
- 24
- open now
- 1
- in phase 3
- 6
- first study started
- 2020
Keep track of what changes. Save the camostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 2020 (13)
| Year | Studies |
|---|---|
| 2020 | 13 |
| 2021 | 9 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 16
- Phase 3
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 17
Who runs them
Industry 6 · Other 18
Stanford University (3) · Daewoong Pharmaceutical Co. LTD. (3) · Ono Pharmaceutical Co. Ltd (2) · Yale University (2) · Heinrich-Heine University, Duesseldorf (2) · University of Aarhus (1) · Seoul National University Hospital (1) · Alan Bryce (1)
Often tested with
Tested in the same studies.
Bamlanivimab (1) · Amubarvimab (1) · Romlusevimab (1) · Cilgavimab and tixagevimab drug combination (1) · Interferon beta-1a (1) · Interferon Beta-1a Inhalation Solution SNG001 (1) · Ogalvibart (1) · Crexavibart (1)
Studies
Open first, then newest update. How each study uses camostat is read from its arms, and is right about nine times in ten.
Testing it · 24
- Effect Camostat for Kidney Protection in Chronic Kidney DiseaseRecruitingPhase 2Odense University HospitalNCT06794593Written as Camostat Mesylate
- The Impact of Camostat Mesilate on COVID-19 InfectionCompletedPhase 1/2University of AarhusNCT04321096Written as Camostat Mesilate
- Camostat Mesylate for Protein-losing Enteropathy After Fontan OperationCompletedPhase 2Seoul National University HospitalNCT05474664Written as Camostat mesylate
- Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19CompletedPhase 2Alan BryceNCT04470544Written as Camostat Mesilate
- The Potential of Camostat in COVID-19TerminatedPhase 2University Hospital, GhentNCT04625114Written as Camostat
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as Camostat
- Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male SubjectsCompletedPhase 1Ono Pharmaceutical Co. LtdNCT04451083Written as FOY-305
- A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)CompletedPhase 3Ono Pharmaceutical Co. LtdNCT04657497Written as FOY-305
- A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)TerminatedPhase 2Cancer Research UKNCT04455815Written as Camostat
- Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04713176Written as DWJ1248 with Remdesivir
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master ProtocolCompletedPhase 2Stanford UniversityNCT04662086Written as Camostat
- COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-ProtocolTerminatedPhase 2Stanford UniversityNCT04662073Written as Camostat
- A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2TerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04721535Written as DWJ1248
- Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy VolunteersCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT04782505Written as DWJ1248
- The DAWN Antivirals Trial for Ambulatory COVID-19 PatientsTerminatedPhase 3KU LeuvenNCT04730206Written as Camostat
- Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 PatientsCompletedPhase 2Stanford UniversityNCT04524663Written as Camostat Mesilate
- The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsWithdrawnPhase 1/2Yale UniversityNCT04435015Written as Camostat Mesylate
- Camostat Mesylate in COVID-19 OutpatientsCompletedPhase 2Yale UniversityNCT04353284Written as Camostat Mesilate
- Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk IndividualsCompletedPhase 2Heinrich-Heine University, DuesseldorfNCT04681430Written as Camostat Mesilate
- CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult PatientsTerminatedPhase 3Assistance Publique - Hôpitaux de ParisNCT04608266Written as Camostat Mesylate
See all 24 studies that test camostat →
As the comparator · 1 — what is tested is compared with camostat
Codes
What other systems call camostat · ClinicalTrials.gg INT003030
- MeSH (NLM) C034532camostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0FD207WKDUCAMOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q5026909camostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73213CamostatOne source FDA
- DrugBank DB13729One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C034532 | camostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0FD207WKDU | CAMOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5026909 | camostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73213 | Camostat | One source FDA |
| DrugBank | DB13729 | — | One source Wikidata |
Also registered as camostat mesylate (UNII 451M50A1EQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.